Interferon Kappa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Interferon Kappa
Accession Number
DB15749
Description

Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Interferons
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • IFN‐κ
External IDs
  • Interferon Kappa

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Significant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN-κ acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN-κ binds at the same receptors, which are interferon-α/β receptor 1(IFNAR1) and IFNAR2.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA: Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001 Oct 26;276(43):39765-71. doi: 10.1074/jbc.M102502200. Epub 2001 Aug 20. [PubMed:11514542]
  2. de Weerd NA, Nguyen T: The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012 May;90(5):483-91. doi: 10.1038/icb.2012.9. Epub 2012 Mar 13. [PubMed:22410872]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 15:55 / Updated on August 13, 2020 01:02

Pm 6